Dabigatran must be used carefully: literature review and recommendations for management of adverse events

References

• Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(7):2N–9N.
   PubMed Web of Science ®Google Scholar
• Brass L, Krumholz L, Scinto J, et al. War farin use following ischemic stroke among medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093–2100.9801175
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa090556119717844
   PubMed Web of Science ®Google Scholar
• Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Semin Thromb Hemost. 2018.
   PubMedGoogle Scholar
• Jelani Q, Gordon R, Schussheim A. Dabigatran-induced spontaneous hemopericardium and cardiac tamponade. Tex Heart Inst J. 2017;44(5):370–372. doi:10.14503/THIJ-16-607329259514
   PubMed Web of Science ®Google Scholar
• Huang J, Lin W, Lv D, et al. Dabigatran-induced massive spontaneous hemothorax. Drug Saf Case Rep. 2017;4(1):12. doi:10.1007/s40800-017-0056-x28940001
   PubMedGoogle Scholar
• Otteno H, Smith E, Huffaker RK. Dabigatran induced hemorrhagic cystitis in a patient with painful bladder syndrome. Case Rep Urol. 2014;2014.
   Google Scholar
• Carter A, Sarda P, George M, et al. Hip arthroplasty fatality related to dabigatran induced gastrointestinal haemorrhage. Ann R Coll Surg Engl. 2014;96(1):e01–e03. doi:10.1308/003588414X13824511649779
   PubMedGoogle Scholar
• Dumkow LE, Voss JR, Peters M, Jennings DL. Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma. Am J Health Syst Pharm. 2012;69(19):1646–1650. doi:10.2146/ajhp12005522997117
   PubMed Web of Science ®Google Scholar
• Wychowski MK, Kouides PA. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):e10. doi:10.1345/aph.1Q74722496474
   PubMedGoogle Scholar
• Cano EL, Miyares MA. Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother. 2012;10(2):160–163. doi:10.1016/j.amjopharm.2012.02.00422386824
   PubMedGoogle Scholar
• Matsuura H, Suto K, Yasuhara H, et al. Longitudinal sloughing mucosal casts: dabigatran-induced oesophagitis. Eur Heart J. 2018;39(36):3400. doi:10.1093/eurheartj/ehw18030169635
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Takasugi N, Goto T, et al. Very late-onset dabigatran-induced esophageal injury. Can J Cardiol. 2017;33(4):554.e15–554. e16. doi:10.1016/j.cjca.2016.12.017
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Sawada T, Kobayashi T, Yamagishi M. Dabigatran-induced exfoliative esophagitis. Intern Med. 2016;55(13):1815. doi:10.2169/internalmedicine.55.660627374691
   PubMed Web of Science ®Google Scholar
• Shibagaki K, Taniguchi H, Goto D, Kobayashi K, Kinoshita Y. Dabigatran-induced asymptomatic esophageal mucosal injury. Gastrointest Endoac. 2016;83(2):472–474. doi:10.1016/j.gie.2015.08.028
   PubMed Web of Science ®Google Scholar
• Izumikawa K, Inaba T, Mizukawa S, et al. Two cases of dabigatran-induced esophageal ulcer indicating the usefulness of drug administration guidance. Nihon Shokakibyo Gakkai zasshi. 2014;111(6):1096–1104.24898488
   PubMedGoogle Scholar
• Zimmer V, Casper M, Lammert F. Extensive dabigatran-induced exfoliative esophagitis harboring squamous cell carcinoma. Endoscopy. 2014;46(S 01):E273–E274. doi:10.1055/s-0034-136578224906097
   PubMed Web of Science ®Google Scholar
• Ootani A, Hayashi Y, Miyagi Y. Dabigatran-induced esophagitis. Clin Gastroenterol Hepatolthe. 2014;12(7):e55. doi:10.1016/j.cgh.2013.09.010
   PubMed Web of Science ®Google Scholar
• Singh S, Savage L, Klein M, et al. Case report: severe necrotic oesophageal and gastric ulceration associated with dabigatran. BMJ Case Rep. 2013;2013.
   Google Scholar
• Patel S, Hossain MA, Ajam F, et al. Dabigatran-induced acute interstitial nephritis: an important complication of newer oral anticoagulation agents. J Clin Med Res. 2018;10(10):791. doi:10.14740/jocmr3569w30214652
   PubMedGoogle Scholar
• Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012. doi:10.1177/1076029611435840
   PubMed Web of Science ®Google Scholar
• Zaleski M, Dabage N, Paixao R, Muniz J. Dabigatran-induced hyperkalemia in a renal transplant recipient: a clinical observation. J Clin Pharmacol. 2013;53(4):456–458. doi:10.1002/jcph.2123381788
   PubMed Web of Science ®Google Scholar
• Stöllberger C, Krutisch G, Finsterer J, Wolf HM. Dabigatran-induced lupus temporarily preventing blood group determination. Blood Coagul Fibrinolysis. 2014;25(6):625–627. doi:10.1097/MBC.000000000000009924572762
   PubMed Web of Science ®Google Scholar
• Mancano MA. ISMP adverse drug reactions: influenza vaccine-induced Stevens-Johnson Syndrome; vilazodone-induced nightmares; dabigatran-induced pustular eruptions; neurotoxic and cardiotoxic symptoms after cannabis concentrate exposure; rosuvastatin-induced skin eruption. Hosp Pharm. 2018;53(1):15–17. doi:10.1177/001857871773972729434381
   PubMedGoogle Scholar
• Eid TJ, Shah SA. Dabigatran-induced rash. Am J Health Syst Pharm. 2011;68(16):1489–1490. doi:10.2146/ajhp11008821817079
   PubMed Web of Science ®Google Scholar
• Vega-Molpeceres S, Just SM, Escoda GM. Dabigatran induced exanthema. Rev Clin Esp. 2010;210(11):590.21074757
   PubMed Web of Science ®Google Scholar
• Whitehead H, Boyd JM, Blais DM, et al. Drug-induced exanthem following dabigatran. Ann Pharmacother. 2011;45(10):e53. doi:10.1345/aph.1P57221881034
   PubMed Web of Science ®Google Scholar
• Blommel ML, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm. 2011;68(16):1506–1519. doi:10.2146/ajhp10034821817082
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa090659819966341
   PubMed Web of Science ®Google Scholar
• Lanas-Gimeno A, Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin Drug Saf. 2017;16(6):673–685. doi:10.1080/14740338.2017.132587028467190
   PubMed Web of Science ®Google Scholar
• Pellicano R, Ribaldone DG, Fagoonee S, et al. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva med. 2016;58(4):304–317.27716738
   PubMed Web of Science ®Google Scholar
• Friedman AC, Oyewole MA. Pill-induced esophageal injury. Case reports and review of the medical literature. Dig Dis Sci. 1983;28:174–182.6825537
   PubMed Web of Science ®Google Scholar
• Toya Y, Nakamura S, Tomita K, et al. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016;31(3):610–614. doi:10.1111/jgh.1302426102078
   PubMed Web of Science ®Google Scholar
• Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11(3):246–52. e5. doi:10.1016/j.cgh.2012.10.02123103906
   PubMed Web of Science ®Google Scholar
• Eriksson B, Dahl O, Buller R, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Throm Haem. 2004;3(1):103–111. doi:10.1111/j.1538-7836.2004.01100.x
   Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–295. doi:10.2165/00003088-200847050-0000118399711
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402. doi:10.1001/archinternmed.2011.166622231617
   PubMed Web of Science ®Google Scholar
• Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969–974. doi:10.1056/NEJMoa02049612324552
   PubMed Web of Science ®Google Scholar